Onxeo aims to become a global leader in oncology focused on orphan diseases, supported by an attractive product pipeline:
Partnerships are key to Onxeo’s growth strategy.
Onxeo has a successful experience in licensing deals with pharmaceutical companies around the world.
The Company has already led two programmes to registration, including with the US (FDA) and European (EMA) authorities, sold or licensed four drugs and successfully executed one international merger (Topotarget, Denmark in 2014) and one acquisition (DNA Therapeutics in 2016).
Onxeo is highly interested in collaborative opportunities – co-development, and out-licensing.
Onxeo is also committed to build up its portfolio of innovative products through in-licensing deals. We are looking for early stage compounds - 1 to 2 years from IND - or more advanced projects, in the field of orphan oncology, with a focus on DNA-targeting mechanisms of action.
If you have a partnering opportunity in our area of expertise or an interest in our products, please contact us at email@example.com